OBI Pharma, Inc. (TPEX:4174)
Taiwan · Delayed Price · Currency is TWD 38.55
+0.15 (0.39%)
At close: Mar 24, 2026
OBI Pharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 58.58 | 62.68 | 41.55 | 4.71 | 18.77 | |
Revenue Growth (YoY) | -6.55% | 50.85% | 781.96% | -74.90% | -86.68% |
Cost of Revenue | 136.1 | 138.95 | 115.05 | 44.86 | 44.36 |
Gross Profit | -77.53 | -76.27 | -73.5 | -40.14 | -25.59 |
Selling, General & Admin | 361.96 | 326.78 | 319.28 | 309.76 | 240.83 |
Research & Development | 1,729 | 1,968 | 1,697 | 1,773 | 1,450 |
Operating Expenses | 2,091 | 2,295 | 2,016 | 2,083 | 1,690 |
Operating Income | -2,169 | -2,372 | -2,090 | -2,123 | -1,716 |
Interest Expense | -13.13 | -10.65 | -7.94 | -3.99 | -3.8 |
Interest & Investment Income | 29.79 | 40.07 | 92.96 | 49.93 | 6.46 |
Earnings From Equity Investments | -201.99 | -233.18 | -163.58 | - | - |
Currency Exchange Gain (Loss) | - | 25.44 | 13.11 | 156.68 | -42.06 |
Other Non Operating Income (Expenses) | 94.64 | 9.66 | 8.72 | 4.06 | 8.22 |
EBT Excluding Unusual Items | -2,259 | -2,540 | -2,147 | -1,916 | -1,747 |
Gain (Loss) on Sale of Investments | - | 0.26 | 879.32 | -1.02 | 20.03 |
Gain (Loss) on Sale of Assets | - | 43.72 | -0.39 | 0.01 | -15.08 |
Asset Writedown | - | - | -5.96 | - | - |
Other Unusual Items | - | - | -2 | - | - |
Pretax Income | -2,259 | -2,496 | -1,276 | -1,917 | -1,742 |
Income Tax Expense | -2.73 | -3.56 | -9.59 | -17.77 | -24.36 |
Earnings From Continuing Operations | -2,257 | -2,493 | -1,266 | -1,899 | -1,718 |
Minority Interest in Earnings | 203.93 | 182.62 | 219.49 | 285.41 | 187.2 |
Net Income | -2,053 | -2,310 | -1,046 | -1,614 | -1,531 |
Net Income to Common | -2,053 | -2,310 | -1,046 | -1,614 | -1,531 |
Shares Outstanding (Basic) | 132 | 117 | 115 | 111 | 99 |
Shares Outstanding (Diluted) | 132 | 117 | 115 | 111 | 99 |
Shares Change (YoY) | 12.58% | 1.99% | 3.12% | 11.65% | 0.18% |
EPS (Basic) | -15.61 | -19.78 | -9.14 | -14.53 | -15.39 |
EPS (Diluted) | -15.61 | -19.78 | -9.14 | -14.53 | -15.39 |
Free Cash Flow | -2,064 | -1,947 | -1,755 | -1,874 | -1,306 |
Free Cash Flow Per Share | -15.70 | -16.67 | -15.32 | -16.88 | -13.13 |
Gross Margin | -132.36% | -121.69% | -176.89% | - | -136.32% |
Operating Margin | -3702.58% | -3783.67% | -5029.70% | -45059.69% | -9141.35% |
Profit Margin | -3504.61% | -3685.54% | -2518.65% | -34258.46% | -8154.10% |
Free Cash Flow Margin | -3523.70% | -3105.95% | -4223.71% | -39786.71% | -6956.13% |
EBITDA | -1,942 | -2,210 | -1,911 | -1,935 | -1,559 |
D&A For EBITDA | 227.16 | 161.42 | 179.2 | 188.01 | 157.24 |
EBIT | -2,169 | -2,372 | -2,090 | -2,123 | -1,716 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.